Journal of Clinical Investigation , 129 , 40324040
An example of low androgens, but a preference for the 5a reductase pathway, taken from a FUTURE WOMAN hormone test report
In the UK, BPC-157 is not currently licensed as a medicine for human use by the MHRA (Medicines and Healthcare products Regulatory Agency)
TB-500 makes more sense when: The injury is deep or hard to reach with an injection (spine, deep hip, cardiac tissue) You're dealing with multiple injuries at the same time Recovery involves systemic inflammation rather than something localized BPC-157 makes more sense when: The injury is easy to inject near (knee, shoulder, elbow, ankle) Gut healing is the main goal, since BPC-157's strongest documented effects are in the GI tract You're targeting a neurological issue through a localized administration route Neither peptide has human RCT data for musculoskeletal use yet
Starting at a lower dose and gradually increasing under medical supervision is advised